Markets:

Overview

News

Currencies

International

Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

0.8875 +0.0175 (+2.01%)

Streaming Delayed Price Updated: 10:48 AM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs

February 16, 2022

In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under...

From Jaguar Health, Inc.

Via AccessWire

Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency

February 15, 2022

SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business model SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health...

From Jaguar Health, Inc.

Via AccessWire

Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs

February 10, 2022

Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX),...

From Jaguar Health, Inc.

Via AccessWire

Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)

February 01, 2022

Study results expected to be described in upcoming presentations and publications CDD patients face intestinal failure (IF), similar to patients suffering from short bowel syndrome (SBS) - the priority...

From Jaguar Health, Inc.

Via AccessWire

Why Jaguar Health Shares Are Rising ↗

January 12, 2022

Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher ...

Via Benzinga

Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics

January 24, 2022

Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has...

From Jaguar Health, Inc.

Via AccessWire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 13, 2022

Gainers Stealth BioTherapeutics (NASDAQ:MITO

Via Benzinga

Jaguar Health Provides Corporate Update and Outlines 2022 Milestones

January 13, 2022

2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure...

From Jaguar Health, Inc.

Via AccessWire

20 Stocks Moving in Thursday's Pre-Market Session ↗

January 13, 2022

Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-...

Via Benzinga

50 Biggest Movers From Yesterday ↗

January 13, 2022

Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for...

Via Benzinga

28 Stocks Moving In Wednesday's Mid-Day Session ↗

January 12, 2022

Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing...

Via Benzinga

NIO Stock Alert: The Steel Deal That Has EV Maker Nio Driving Higher ↗

January 12, 2022

Nio (NIO) stock is rising higher on Wednesday following news of a deal with Baoshan Iron & Steel and we've got all the details!

Via InvestorPlace

Chinese Tech Stocks: Why Are DIDI, JD and BABA Moving Higher Today? ↗

January 12, 2022

Chinese tech stocks are on the move Wednesday and we're diving into the latest news that has these shares heading higher today!

Via InvestorPlace

JAGX Stock Alert: What Is Going on With Jaguar Health Today? ↗

January 12, 2022

JAGX stock is rallying on Wednesday after a rough year thanks to news that Oasis Capital has taken a 10% stake in Jaguar Health.

Via InvestorPlace

Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida

January 12, 2022

Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDA U.S. veterinarians,...

From Jaguar Health, Inc.

Via AccessWire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 12, 2022

Gainers Immuron (NASDAQ:IMRN) stock moved upwards by 69.5% to $4.44 during Wednesday's pre-market session. The market value of their outstanding shares is at $25.2...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 12, 2022

Good morning, trader! Let's get this party started with a dive into the biggest pre-market stock movers to watch for Wednesday!

Via InvestorPlace

15 Stocks Moving in Wednesday's Pre-Market Session ↗

January 12, 2022

Gainers Kidpik Corp. (NASDAQ: PIK) rose 34.4% to $8.13 in pre-market trading after jumping more than 27% on Tuesday. Kidpik, last month, posted a Q3 loss of $0.22 per share....

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 11, 2022

Gainers Jaguar Health (NASDAQ:JAGX) stock...

Via Benzinga

Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

January 04, 2022

The Canalevia.com website, a resource for veterinarians and dog owners, is now live Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of...

From Jaguar Health, Inc.

Via AccessWire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 22, 2021

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV...

Via Benzinga

Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs

December 22, 2021

By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /...

From Jaguar Health, Inc.

Via AccessWire

FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs ↗

December 22, 2021

The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 21, 2021

Gainers BioRestorative Therapies (NASDAQ:BRTX...

Via Benzinga

JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher ↗

December 21, 2021

Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment.

Via InvestorPlace

Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA

December 21, 2021

From Jaguar Health, Inc.

Via AccessWire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 21, 2021

Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4...

Via Benzinga

Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs

December 20, 2021

SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics...

From Jaguar Health, Inc.

Via AccessWire

European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome

December 13, 2021

The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar Health SAN...

From Jaguar Health, Inc.

Via AccessWire

Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)

December 10, 2021

Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients...

From Jaguar Health, Inc.

Via AccessWire

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

All News about Jaguar Health, Inc. - Common Stock

Starting at /week.